A PHASE 2 STUDY OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) IN COMBINATION WITH BNT116 (FIXVAC LUNG) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50%. - R2810-ONC-2045

Regeneron Pharmaceuticals Inc.0 个研究点目标入组 100 人开始时间: 2023年8月3日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Participants with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic) disease who received no prior systemic treatment for recurrent or metastatic NSCLC, Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample as defined in the protocol., Expression of Programmed cell death ligand-1 (PD-L1) in =50% of tumor cells stained using the VENTANA PD-L1 (SP263) Assay as performed by a central laboratory, Participants must have at least 1 radiographically measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria, Eastern Cooperative Oncology Group (ECOG) performance status =1, Other protocol-defined inclusion criteria apply

排除标准

•Participants who have never smoked, defined as smoking =100 cigarettes in a lifetime, Another malignancy that is progressing or requires treatment, with the exception of non-melanomatous skin cancer that has undergone potentially curative therapy, in situ cervical carcinoma, or any other localized tumor that has been treated, and the participant is deemed to be in complete remission for at least 2 years prior to enrollment, and no additional therapy is required during the study period, Documented or suspected ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as defined in the protocol, Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to CTCAE grade =1 or baseline with the exception of alopecia and peripheral neuropathy., Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Anti-PD-(L)1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is >12 months prior to enrollment., Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy such as anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA-4) antibodies as long as the last dose is >6 months prior to enrollment, History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by New York Heart Association Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment., Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling., Other protocol-defined Exclusion criteria apply, Active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment, Participants with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase 1 (ROS1) fusions, Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment, Participants with history of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years, Prior splenectomy, Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol, Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (imTEAEs), Participants requiring corticosteroid therapy (>5 mg prednisone/da

研究者

发起方

Regeneron Pharmaceuticals Inc.

相似试验

进行中（未招募）

1 期

Cemiplimab and ISA101b Vaccine in Adult Participants with Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression after First Line ChemotherapyRecurrent/Metastatic HPV16 Cervical CancerMedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862

EUCTR2020-001239-29-ITREGENERON PHARMACEUTICALS, INC.103

进行中（未招募）

1 期

EUCTR2020-003652-32-ESISA Therapeutics B.V.86

进行中（未招募）

1 期

EUCTR2020-003652-32-BEISA Therapeutics B.V.65

进行中（未招募）

1 期

An experimental study in men and women with head and neck cancer to test the efficacy, safety and tolerability of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activates part of the immune systemRecurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC)MedDRA version: 21.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-003652-32-ITISA Therapeutics B.V.86

进行中（未招募）

1 期

EUCTR2020-003652-32-CZISA Therapeutics B.V.86